OBIO

Market Performance: Drug shares are lagging behind the market, down approximately 0.9%, with Corcept Therapeutics and Phathom Pharmaceuticals experiencing significant declines of 15.5% and 11.3%, respectively.

Author's Perspective: The views expressed in the article reflect the author's opinions and do not necessarily represent those of Nasdaq, Inc.

Quarterly Performance: Orchestra BioMed Holdings, Inc. reported a quarterly loss of $0.43 per share, matching expectations but slightly worse than the previous year's loss of $0.37. Revenues for the quarter were $0.25 million, falling short of estimates by 67.85%.

Market Outlook: The company's stock has risen about 10% this year, outperforming the S&P 500's decline. Future performance will depend on management's commentary and earnings estimate revisions, with current consensus estimates projecting further losses in upcoming quarters.

Power Solutions International Earnings Surge: Power Solutions International, Inc. reported a significant increase in fourth-quarter earnings, rising to $1.01 per share from 36 cents the previous year, leading to a 9.8% jump in its stock price during pre-market trading.

Stock Movements in Pre-Market Trading: Several stocks experienced notable changes in pre-market trading, with Tenon Medical, Inc. soaring by 91.2% after FDA clearance, while Integrated Media Technology Limited saw a sharp decline of 30% following a previous surge.

AVIM Therapy Presentation: Orchestra BioMed presented data on atrioventricular interval modulation (AVIM) therapy at the Technology and Heart Failure Therapeutics 2025 Conference, showing significant improvements in echocardiographic markers of diastolic dysfunction in hypertensive patients with diastolic dysfunction.

Study Findings: The MODERATO II study revealed that AVIM therapy led to notable reductions in systolic blood pressure and improved measures of diastolic function, indicating enhanced myocardial relaxation and compliance in patients with diastolic dysfunction.

Analyst Coverage Initiations: Several Wall Street analysts have initiated coverage on various companies, including Kopin Corporation with a Buy rating and a price target of $2, EHang Holdings Limited with an Outperform rating, and Corvus Pharmaceuticals with a Buy rating and a price target of $11.

Stock Performance Insights: Analysts provided insights into the current stock prices, noting that Kopin shares closed at $1.36, EHang at $15.74, Corvus at $5.35, Norwood Financial at $27.20, and Orchestra BioMed at $4.00, indicating potential growth opportunities based on their ratings.

Insider Trading Activity: David P Hochman purchased 4,000 shares of $OBIO on December 23, 2024, increasing his holdings to 579,498 shares. In the past six months, insiders have made 17 trades involving $OBIO stock, with 9 purchases and 8 sales.

Institutional Investor Movements: In the latest quarter, 26 institutional investors increased their positions in $OBIO, while 19 reduced theirs, indicating mixed sentiment among larger investors regarding the stock.

Orchestra BioMed Presentations: Orchestra BioMed Holdings, Inc. announced two presentations at the 2024 Innovation in Cardiology Intervention meeting, focusing on their BACKBEAT global pivotal study and the AVIM therapy for treating uncontrolled hypertension in patients with dual-chamber pacemakers.

AVIM Therapy Overview: The AVIM therapy aims to significantly lower blood pressure by modulating the autonomic nervous system, with promising results from pilot studies indicating substantial reductions in systolic blood pressure among treated patients.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Community of Traders: The platform boasts a community of over 10,000 serious traders who benefit from exclusive stories and accurate market intelligence provided by Benzinga reporters.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Community of Traders: The platform boasts a community of over 10,000 serious traders who benefit from exclusive stories and accurate market intelligence provided by Benzinga reporters.

Financial Performance and Business Updates: Orchestra BioMed reported a net loss of $15.4 million for Q3 2024, an increase in revenue to $1 million, and ongoing advancements in their BACKBEAT study for AVIM therapy in hypertension patients, alongside preparations for coronary pivotal studies for the Virtue SAB program.

Strategic Partnerships and Innovations: The company is collaborating with Medtronic on AVIM therapy and restructuring its partnership with Terumo for the Virtue SAB, while also highlighting positive data from Vivasure Medical's PerQseal device, which may lead to regulatory approval in 2025.

Entera Bio's Quarterly Performance: Entera Bio Ltd. reported a quarterly loss of $0.08 per share, missing the Zacks Consensus Estimate of a loss of $0.05, while revenues reached $0.04 million, surpassing expectations and showing growth from zero revenues a year ago.

Market Outlook and Comparisons: Despite the earnings miss, Entera Bio shares have risen 191.7% this year, outperforming the S&P 500; however, the stock holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market, as investors await further revisions on earnings estimates.

Company Presentation: Orchestra BioMed will present at the Jefferies London Healthcare Conference from November 19-21, 2024, with a fireside chat scheduled for November 19 at 1:00 PM GMT.

Product Development Focus: The company is advancing its AVIM therapy for hypertension and Virtue SAB for atherosclerotic artery disease through strategic partnerships with Medtronic and Terumo.

Travere Therapeutics Stock Performance: Travere Therapeutics (TVTX) shares increased by 11.6% to $15.23 following the FDA's full approval of its drug Filspari for treating primary IgA nephropathy, contributing to a 37.5% gain over the past month. The company is expected to report a quarterly loss of $0.71 per share and revenues of $59.42 million, reflecting significant year-over-year growth.

Industry Context and Recommendations: Travere operates in the Medical - Biomedical and Genetics industry, where another company, Orchestra BioMed Holdings, saw a decline in stock value. Zacks Investment Research suggests monitoring stocks like TVTX due to positive earnings estimate revisions that may lead to further price appreciation.

Insider Buying at Orchestra BioMed: David P. Hochman purchased 10,000 shares of Orchestra BioMed Holdings (OBIO) at $4.79 each, totaling $47,905, marking his fourth buy in the past year, with previous purchases averaging $5.47 per share.

Insider Buying at TScan Therapeutics: Barbara Klencke bought 5,000 shares of TScan Therapeutics (TCRX) for $5.29 each, totaling $26,450, and has made two prior purchases this year at an average price of $5.43 per share, while current market prices are lower than her purchase.

Coverage Initiation and Price Forecast: HC Wainwright & Co. has initiated coverage of Orchestra BioMed Holdings with a Buy recommendation, projecting a 164.08% upside based on an average one-year price target of $16.32/share from its current price of $6.18/share.

Fund Sentiment and Shareholder Activity: There has been a slight increase in institutional ownership of Orchestra BioMed Holdings, with total shares owned rising by 6.90% over the last three months, while notable shareholders like Rtw Investments and Perceptive Advisors maintained their positions without changes.

Earnings Report: Orchestra BioMed Hldgs reported a second quarter 2024 earnings per share of -45 cents, missing the analyst estimate of -39 cents, while revenue reached $778,000, exceeding expectations of $750,000 by 3.73%.

Automated Coverage: InvestorPlace Earnings utilizes automated data from TradeSmith to provide timely summaries of quarterly earnings reports, highlighting key financial metrics and comparisons to analyst estimates.

Quarterly Performance: Orchestra BioMed Holdings, Inc. reported a quarterly loss of $0.45 per share, missing the Zacks Consensus Estimate and showing a decline in revenues to $0.78 million, which was also below expectations.

Future Outlook: Despite underperforming this year, the company's earnings outlook shows favorable revisions, leading to a Zacks Rank #2 (Buy), suggesting potential for stock outperformance in the near future.

Financial Performance and Business Update: Orchestra BioMed reported a net loss of $16 million for Q2 2024, with total revenue of $0.8 million, while focusing on advancing its AVIM therapy for hypertension and Virtue SAB program through strategic partnerships, particularly with Medtronic and Terumo.

Innovative Therapies and Clinical Studies: The company highlighted the potential of its AVIM therapy to address unmet needs in high-risk hypertension patients, supported by positive clinical data from MODERATO studies, and is actively enrolling participants for the BACKBEAT global pivotal study to further evaluate this therapy's efficacy.